CA2181150A1 - Biologically Active Peptides from Functional Domains of Bactericidal/Permeability-Increasing Protein and Uses Thereof - Google Patents
Biologically Active Peptides from Functional Domains of Bactericidal/Permeability-Increasing Protein and Uses ThereofInfo
- Publication number
- CA2181150A1 CA2181150A1 CA2181150A CA2181150A CA2181150A1 CA 2181150 A1 CA2181150 A1 CA 2181150A1 CA 2181150 A CA2181150 A CA 2181150A CA 2181150 A CA2181150 A CA 2181150A CA 2181150 A1 CA2181150 A1 CA 2181150A1
- Authority
- CA
- Canada
- Prior art keywords
- bactericidal
- permeability
- increasing protein
- biologically active
- functional domains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
Abstract
The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18322294A | 1994-01-14 | 1994-01-14 | |
US08/183,222 | 1994-01-14 | ||
US08/209,762 | 1994-03-11 | ||
US08/209,762 US5733872A (en) | 1993-03-12 | 1994-03-11 | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
PCT/US1994/010427 WO1995019372A1 (en) | 1994-01-14 | 1994-09-15 | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2181150A1 true CA2181150A1 (en) | 1995-07-20 |
CA2181150C CA2181150C (en) | 1999-12-14 |
Family
ID=26878892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002181150A Expired - Fee Related CA2181150C (en) | 1994-01-14 | 1994-09-15 | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
Country Status (5)
Country | Link |
---|---|
US (5) | US5733872A (en) |
JP (1) | JPH09507501A (en) |
CN (1) | CN1071759C (en) |
CA (1) | CA2181150C (en) |
WO (1) | WO1995019372A1 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198541A (en) * | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
US5733872A (en) * | 1993-03-12 | 1998-03-31 | Xoma Corporation | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
US6214789B1 (en) * | 1993-03-12 | 2001-04-10 | Xoma Corporation | Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
US5447913A (en) | 1994-03-11 | 1995-09-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
JPH10508576A (en) * | 1994-09-15 | 1998-08-25 | ゾーマ コーポレイション | Antifungal peptide |
JP2001520631A (en) * | 1995-07-20 | 2001-10-30 | ゾーマ コーポレイション | Antifungal peptide |
US5741779A (en) | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
DE69703689T2 (en) * | 1996-05-10 | 2001-05-10 | Xoma Technology Ltd | THERAPEUTIC APPLICATIONS OF BPI PROTEIN PRODUCTS FOR TREATING HUMAN MENINGOCOCCÄMIA |
AU736096B2 (en) * | 1996-05-23 | 2001-07-26 | Xoma Corporation | Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma |
US5888973A (en) * | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
US6482796B2 (en) * | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
US6013631A (en) * | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
JP2002527490A (en) | 1998-10-22 | 2002-08-27 | イーライ・リリー・アンド・カンパニー | How to treat sepsis |
US6399570B1 (en) * | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
US6242219B1 (en) | 1999-03-18 | 2001-06-05 | Xoma (Us) Llc | Methods for recombinant peptide production |
CU22976A1 (en) * | 1999-06-06 | 2004-09-09 | Ct Ingenieria Genetica Biotech | PEPTIDE SEQUENCE ANALOGS DERIVED FROM THE PROTEIN LINKING LIPOPOLISACÁRIDO (LPS) THAT HAVE EFFICIENT CAPACITY OF LPS NEUTRALIZATION |
DK1196440T3 (en) * | 1999-06-25 | 2004-07-12 | Xoma Technology Ltd | Therapeutic peptides derived from BPI sub-sequences |
JP2004517865A (en) * | 2000-12-01 | 2004-06-17 | ゾーマ テクノロジー リミテッド | Regulation of pericyte proliferation using BPI protein products or inhibitors |
US6706688B2 (en) * | 2001-03-09 | 2004-03-16 | Paula Sundstrom | Methods for regulating bud-hypha transitions and cAMP levels by the adenylate cyclase-associated protein gene, CAP1 |
US7270975B2 (en) * | 2001-03-09 | 2007-09-18 | Trustees Of Dartmouth College | Methods for regulating bud-hypha transitions and cAMP levels in Candida albicans |
US20050154536A1 (en) * | 2001-08-30 | 2005-07-14 | The University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Two-part drug discovery system |
US20030087285A1 (en) * | 2001-08-30 | 2003-05-08 | Chow Carson C. | Algorithm for estimating the outcome of inflammation following injury or infection |
JP4959110B2 (en) * | 2002-02-07 | 2012-06-20 | マサチューセッツ インスティテュート オブ テクノロジー | Anti-pathogen treatment |
CA2492008C (en) | 2002-03-29 | 2012-06-26 | Xoma Technology Ltd. | Multigenic vectors plasmids and methods for increasing expression of recombinant polypeptides |
SE0301431D0 (en) | 2003-05-19 | 2003-05-19 | Dermagen | Novel antimicrobial peptides |
US7498309B2 (en) * | 2003-11-29 | 2009-03-03 | Sangstat Medical Corporation | Pharmaceutical compositions for bioactive peptide agents |
US20050282755A1 (en) * | 2004-03-18 | 2005-12-22 | Ansata Therapeutics, Inc. | Compositions having antimicrobial activity and uses thereof |
US20060004185A1 (en) * | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
SE0402807D0 (en) * | 2004-11-17 | 2004-11-17 | Dermagen Ab | Novel antimicrobial peptides |
US20090312265A1 (en) * | 2006-02-10 | 2009-12-17 | Dermagen Ab | Novel antimicrobial peptides and use thereof |
US8076286B2 (en) | 2006-02-10 | 2011-12-13 | Dermagen Ab | Antimicrobial peptides and use thereof |
US8227406B2 (en) * | 2006-05-16 | 2012-07-24 | Dermagen Ab | Antimicrobial peptides |
WO2008070116A2 (en) * | 2006-12-04 | 2008-06-12 | Concert, Llc | Topical compositions for treatment of skin conditions |
US20090048160A1 (en) * | 2007-08-17 | 2009-02-19 | Bannerman Douglas D | Antimicrobial activity of bovine bactericidal/permeability-increasing protein (BPI)-derived peptides against Gram-negative bacterial mastitis isolates |
CA2747995A1 (en) | 2008-12-23 | 2010-07-01 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
US8415307B1 (en) | 2010-06-23 | 2013-04-09 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
AU2014263279B2 (en) | 2013-05-10 | 2018-02-15 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Antimicrobial peptide |
GB201507722D0 (en) | 2015-05-06 | 2015-06-17 | Norwegian Univ Sci & Tech Ntnu | Anti-bacterial agents and their use in therapy |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5028530A (en) * | 1985-01-28 | 1991-07-02 | Xoma Corporation | AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques |
US5206154A (en) * | 1985-01-28 | 1993-04-27 | Xoma Corporation | Method of producing cecropins by microbiological techniques |
EP0220308A1 (en) * | 1985-04-30 | 1987-05-06 | Scripps Clinic And Research Foundation | Acute phase protein modulating endotoxic activity of lipopolysaccharides, compositions and methods |
US5262403A (en) * | 1986-03-10 | 1993-11-16 | Board Of Regents, The University Of Texas System | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II |
IL90356A0 (en) * | 1988-05-27 | 1989-12-15 | Magainin Sciences Inc | Amphiphilic peptides and pharmaceutical compositions containing them |
US5086164A (en) * | 1989-01-10 | 1992-02-04 | Repligen Corporation | Novel methods and compositions for treatment of angiogenic diseases |
US5171739A (en) * | 1989-02-14 | 1992-12-15 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and preventation thereof using a BPI protein |
US5073542A (en) * | 1989-06-07 | 1991-12-17 | Magainin Sciences Inc. | CPF peptide compositions and their use in inhibiting growth of target cells or a virus |
US5112946A (en) * | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
US5045531A (en) * | 1989-12-18 | 1991-09-03 | Magainin Sciences Inc. | Wound treatment employing biologically active ion channel forming peptides and proteins |
EP0526570A4 (en) * | 1990-04-27 | 1993-04-21 | Magainin Sciences, Inc. | Composition and treatment with biologically active peptides and anti-parasitic agents or anti-fungal agents |
JPH05507273A (en) * | 1990-05-14 | 1993-10-21 | マゲイニン サイエンセズ インコーポレーテッド | Compositions of bioactive peptides having D-amino acid residues and methods of treatment using the same |
US5208220A (en) * | 1990-06-27 | 1993-05-04 | Magainin Pharmaceuticals, Inc. | Composition and treatment with biologically active peptides and antibiotics which inhibit DNA gyrase |
WO1992000090A1 (en) * | 1990-06-27 | 1992-01-09 | Magainin Pharmaceuticals Inc. | Composition and treatment with biologically active peptides and antibiotics which inhibit dna gyrase |
EP0541716A1 (en) * | 1990-07-27 | 1993-05-19 | Repligen Corporation | Novel methods and compositions for treatment of angiogenic diseases |
EP0563222B1 (en) * | 1990-12-03 | 1998-02-25 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
ZA92943B (en) * | 1991-02-11 | 1992-11-25 | Porro Massimo | Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock |
US5371186A (en) * | 1991-02-11 | 1994-12-06 | Biosynth S.R.L. | Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock |
EP0576669A4 (en) * | 1992-01-16 | 1996-05-08 | Repligen Corp | Novel methods and compositions for treatment of angiogenic diseases |
CA2142306A1 (en) * | 1992-08-21 | 1994-03-03 | Robert E.W. Hancock | Cationic peptides and method for production |
US5733872A (en) * | 1993-03-12 | 1998-03-31 | Xoma Corporation | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
-
1994
- 1994-03-11 US US08/209,762 patent/US5733872A/en not_active Expired - Lifetime
- 1994-09-15 JP JP7519010A patent/JPH09507501A/en not_active Ceased
- 1994-09-15 CA CA002181150A patent/CA2181150C/en not_active Expired - Fee Related
- 1994-09-15 CN CN94194835A patent/CN1071759C/en not_active Expired - Fee Related
- 1994-09-15 WO PCT/US1994/010427 patent/WO1995019372A1/en active IP Right Grant
-
1995
- 1995-06-07 US US08/473,344 patent/US5763567A/en not_active Expired - Lifetime
-
1998
- 1998-06-08 US US09/093,539 patent/US6228834B1/en not_active Expired - Fee Related
-
2001
- 2001-02-21 US US09/790,230 patent/US6495516B1/en not_active Expired - Fee Related
-
2002
- 2002-12-13 US US10/319,786 patent/US7045500B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20040024179A1 (en) | 2004-02-05 |
US5763567A (en) | 1998-06-09 |
US6228834B1 (en) | 2001-05-08 |
CN1141637A (en) | 1997-01-29 |
JPH09507501A (en) | 1997-07-29 |
AU681453B2 (en) | 1997-08-28 |
US6495516B1 (en) | 2002-12-17 |
AU7956094A (en) | 1995-08-01 |
US7045500B2 (en) | 2006-05-16 |
CN1071759C (en) | 2001-09-26 |
US5733872A (en) | 1998-03-31 |
WO1995019372A1 (en) | 1995-07-20 |
CA2181150C (en) | 1999-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2181150A1 (en) | Biologically Active Peptides from Functional Domains of Bactericidal/Permeability-Increasing Protein and Uses Thereof | |
CA2158058A1 (en) | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof | |
CA2180950A1 (en) | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof | |
ZA941771B (en) | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof | |
EP2112161A3 (en) | Peptides that lower blood glucose levels | |
BR9710362A (en) | Pharmaceutical formulation compound uses a compound processes of treatment of a human or animal suffering from a mediated by abnormal activity of protein tyrosine kinase and for the preparation of a compound | |
PT792287E (en) | PEPTIDICAL ANALOGS OF HUMAN MYELIN BASIC PROTEIN | |
TR199501630A2 (en) | Peptide p277 analogues and compositions containing them for diagnosis and treatment of diabetes. | |
AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
CA2263181A1 (en) | Anti-chlamydial methods and materials | |
WO1996028470A3 (en) | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis | |
GB9606040D0 (en) | Active peptide | |
DE69520475D1 (en) | Pharmaceutical composition of biologically active peptides or proteins | |
DE59410423D1 (en) | SERIN-THREONINE-KINASE CONTAINING TUMOR THERAPY AND TUMOR DIAGNOSIS | |
ATE390440T1 (en) | NEUROACTIVE PEPTIDES | |
BG103905A (en) | New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine | |
ATE346091T1 (en) | NEW DIAGNOSTIC REAGENT AND KIT FOR DETECTION OF RICKETSIOSIS | |
DE69630948D1 (en) | PEPTIDES AND MEDICATIONS FOR BONE DISEASES WHICH CONTAIN THESE PEPTIDES AS ACTIVE INGREDIENTS | |
KR950704358A (en) | Cathepsin L specific inhibitory polypeptide | |
NL1000332C1 (en) | Gradual chemical modification of biologically active peptides and proteins. | |
WO1998056810A3 (en) | Lus-1 human protein, its production and use | |
KR960031476A (en) | Novel Antimicrobial Peptides Isolated from Korean Toads (Bufo bufo gargarizans) | |
ZA9510828B (en) | Peptide p277 analogs and phamarceutical compositions comprising them for treatment or diagnosis of diabetes | |
ZA947133B (en) | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof | |
IL114460A0 (en) | Peptide p277 analogs and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |